| In millions, except per share items | Jun-30-21 | Mar-31-21 | Sep-30-20 | Jun-30-20 | Jun-05-20 | Mar-31-20 | Mar-05-20 | Dec-31-19 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 8-K | 10-Q | 8-K | 10-K |
| Revenues: |
| Company product sales | 26.1 | 32.8 | 13.9 | 36.7 | | 23.2 | | 15.7 |
| Topical | 5.5 | 7.0 | 12.0 | 8.8 | | 5.4 | | 10.9 |
| Injectables | 4.2 | 3.6 | 2.0 | 4.2 | | 1.8 | | 4.8 |
| Total revenues [+] | 10.4 | 11.6 | 14.3 | 13.6 | 13.6 | 7.4 | 7.4 | 16.0 |
| Net interest income | | | -8.1 | | | | | -5.9 |
| Revenue growth [+] | -23.2% | 55.6% | -22.3% | -25.9% | -25.9% | -43.2% | -43.2% | -4.8% |
| Company product sales | -29.0% | 41.8% | -23.6% | 105.5% | | 85.4% | | 2.6% |
| Topical | -37.6% | 30.5% | -9.7% | -32.2% | | -40.4% | | 23.7% |
| Injectables | -0.2% | 103.2% | -60.6% | -13.8% | | -49.2% | | -26.1% |
| Contract manufacturing sales | 130.0% | 315.2% | 83.2% | -20.1% | | -63.7% | | -81.4% |
| Cost of goods sold | 13.1 | 12.8 | 14.2 | 11.1 | 11.1 | 8.6 | 8.6 | 14.0 |
| Gross profit | -2.7 | -1.2 | 0.1 | 2.5 | 2.5 | -1.2 | -1.2 | 1.9 |
| Gross margin | -25.9% | -10.5% | 0.8% | 18.4% | 18.4% | -15.6% | -15.6% | 12.2% |
| Selling, general and administrative [+] | 5.7 | 6.3 | 6.5 | 5.0 | 5.0 | 6.7 | 6.7 | 5.1 |
| General and administrative | | | | | | | | 5.1 |
| Research and development | 2.2 | 1.5 | 2.4 | 1.9 | 1.9 | 1.8 | 1.8 | 3.0 |
| Other operating expenses | | | | | 17.5 | | | |
| EBITDA [+] | -9.9 | -8.2 | -7.2 | -2.8 | | -8.0 | | -4.4 |
| EBITDA growth | 258.8% | 2.8% | -482.2% | -217.3% | 139.0% | 617.9% | 253.3% | 17.6% |
| EBITDA margin | -94.7% | -70.5% | -50.0% | -20.3% | -160.8% | -106.8% | -130.0% | -27.8% |
| Depreciation | 0.2 | 0.2 | 1.0 | 1.0 | | 1.0 | | 1.0 |
| EBITA | -10.1 | -8.4 | -8.1 | -3.7 | -21.9 | -8.9 | -9.7 | -5.4 |
| EBITA margin | -96.4% | -72.1% | -56.7% | -27.5% | -160.8% | -120.0% | -130.0% | -34.0% |
| Amortization of intangibles | 0.6 | 0.6 | 0.7 | 0.6 | | 0.7 | | 0.7 |
| EBIT [+] | -10.7 | -8.9 | -8.8 | -4.4 | -21.9 | -9.7 | -9.7 | -6.2 |
| EBIT growth | 144.2% | -7.6% | -4310.0% | -736.6% | 139.0% | 253.3% | 253.3% | 13.4% |
| EBIT margin | -102.2% | -77.2% | -61.4% | -32.1% | -160.8% | -130.0% | -130.0% | -38.7% |
| Non-recurring items [+] | | 0.0 | | | | 8.4 | 8.4 | |
| Asset impairment | | 0.0 | | | | 8.4 | 8.4 | |
| Interest expense | 3.0 | 4.1 | | 7.5 | | 5.9 | | |
| Interest expense | 3.0 | 4.1 | | 7.5 | | 5.9 | | |
| Other income (expense), net [+] | 0.8 | 15.3 | 8.3 | -2.5 | 7.5 | -2.9 | -8.7 | 0.9 |
| Gain (loss) on debt retirement | | 22.4 | 10.9 | | | | | -0.9 |
| Unrealized gain/loss on derivatives | | -3.2 | 4.3 | -4.6 | | -1.3 | | |
| Gain (loss) on foreign currency transactions | 0.8 | -2.1 | 1.9 | 2.1 | | -1.6 | -1.6 | 0.9 |
| Pre-tax income | -12.9 | 2.2 | -0.5 | -14.4 | -14.3 | -26.8 | -26.8 | -5.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 |
| Tax rate | 0.0% | 1.4% | | 0.1% | 0.0% | | | |
| Net income | -12.9 | 2.2 | -0.5 | -14.3 | -14.3 | -26.8 | -26.8 | -5.3 |
| Net margin | -123.3% | 18.6% | -3.6% | -105.5% | -105.5% | -360.4% | -360.4% | -33.2% |
| |
| Basic EPS [+] | ($0.14) | $0.04 | ($0.08) | ($2.56) | ($2.56) | ($4.98) | ($0.50) | ($0.10) |
| Growth | -94.6% | -100.7% | -93.7% | 245.9% | 245.9% | 2971.9% | 207.2% | -63.4% |
| Diluted EPS [+] | ($0.14) | $0.03 | ($0.08) | ($2.56) | ($2.56) | ($4.98) | ($0.50) | ($0.10) |
| Growth | -94.6% | -100.6% | -93.7% | 245.9% | 245.9% | 2971.9% | 207.2% | -63.4% |
| |
| Shares outstanding (basic) [+] | 93.4 | 58.5 | 6.1 | 5.6 | 5.6 | 5.4 | 53.9 | 53.8 |
| Growth | 1570.0% | 985.2% | 13.0% | 3.9% | 3.9% | -90.0% | 0.1% | 0.5% |
| Shares outstanding (diluted) [+] | 93.4 | 77.1 | 6.1 | 5.6 | 5.6 | 5.4 | 53.9 | 53.8 |
| Growth | 1570.0% | 1331.8% | 13.0% | 3.9% | 3.9% | -90.0% | 0.1% | 0.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |